In consent with our results, glial scar markers like GFAP, Neurocan, and Phosphacan, have been demonstrated to be downregulated by the administration of CID1067700 (a Rab7 receptor antagonist involved in the formation of astral sclerosis and glial scars caused by ischemic stroke), which was attributed to the suppressed astrogliosis and glial scar formation as well as improved neurologic deficits as observed in a rat model of ischemic stroke (Qin et al., 2019). The gene discussed is GFAP; the disease is ischemic stroke.